



# The Silent Epidemic

## Early CKD Detection for Kidney and Diabetes Health

Kidney disease is a public health emergency in the UK



**Act early in Kerendia eligible patients like Anne and delay CKD progression in T2D<sup>3\*</sup>**  
In the FIDELIO-DKD study, Kerendia showed a sustained reduction in CKD progression compared to placebo<sup>3,4</sup>



**Add Kerendia to your standard of care for your CKD-associated T2D patients**

NICE recommends **Kerendia<sup>®</sup> (finerenone)**, the first and only UK licensed non-steroidal MRA, as an add-on to standard of care for stage 3 and 4 CKD (with albuminuria) associated with T2D<sup>6\*\*</sup>

Kerendia<sup>®</sup> (finerenone) **slows CKD progression** in T2D and can significantly delay progression of renal disease (vs. placebo)<sup>4</sup>

Diabetic kidney disease is progressive and irreversible; act now with Kerendia<sup>®</sup> (finerenone) to significantly **reduce the risk of renal & CV events** for your patients (vs. placebo)<sup>4</sup>

**\*\*Kerendia is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.<sup>3</sup>**

\*CKD progression defined as the first occurrence of composite of onset of kidney failure, or sustained decrease of eGFR ≥40% from baseline over at least 4 weeks or death due to renal causes.<sup>4</sup>

†Refer to relevant SGLT2i SmPC before prescribing due to variability in licenses.

‡If in line with NICE recommendation and within licence.<sup>6</sup>

ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CKD, chronic kidney disease; CV, cardiovascular; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; MRA, mineralocorticoid receptor antagonist; NICE, National Institute for Health and Care Excellence; SGLT2i, sodium-glucose cotransporter-2 inhibitor; SmPC, Summary of Product Characteristics; T2D, type 2 diabetes; uACR, urinary albumin:creatinine ratio; UK, United Kingdom.

1. Kidney Research UK. Kidney disease: A UK public health emergency – The health economics of kidney disease to 2033. June 2023. Available at: [https://www.kidneyresearchuk.org/wp-content/uploads/2023/06/Economics-of-Kidney-Disease-full-report\\_accessible.pdf](https://www.kidneyresearchuk.org/wp-content/uploads/2023/06/Economics-of-Kidney-Disease-full-report_accessible.pdf). Accessed November 2024; 2. Kidney Research UK. Kidney disease is a public health emergency that threatens to overwhelm the NHS, major new report reveals. June 2023. Available at: <https://www.kidneyresearchuk.org/2023/06/05/kidney-disease-is-a-public-health-emergency-that-threatens-to-overwhelm-the-nhs-major-new-report-reveals/>. Accessed November 2024; 3. Kerendia SmPC; 4. Bakris GL, et al. N Engl J Med 2020;383:2219–2229; 5. NICE. Type 2 diabetes in adults: management [NG28]. Available at: <https://www.nice.org.uk/guidance/ng28>. Accessed November 2024; 6. NICE. Finerenone for treating chronic kidney disease in type 2 diabetes [TA877]. Available at: <https://www.nice.org.uk/guidance/ta877>. Accessed November 2024.

Prescribing information for Kerendia<sup>®</sup> (finerenone) is available via the QR code on the right.

Either click [here](#) or scan the QR code for prescribing information and adverse event reporting information.

For direct access to this prescribing information, please ensure that your device's browser settings have automatic PDF download enabled.

